Texas Senate Bill SB382

Texas 2017 - 85th Regular

• Filed: 12/20/16

Caption

Relating to donation of unused prescription drugs; authorizing a fee.

Impact

The implementation of this bill requires participating providers to adhere to strict standards and procedures for the acceptance, storage, labeling, and dispensing of donated drugs. This encompasses an obligation to ensure that the drugs are tamper-evident and are not controlled substances, misbranded, or adulterated. This regulatory framework aims to facilitate a structured approach to handle prescription drugs that may otherwise go unused, thus potentially enhancing public health outcomes through better drug utilization.

Summary

SB382 introduces regulations concerning the donation and redistribution of unused prescription drugs in Texas. The bill outlines the definitions applicable to the donation process, including terms like 'donor', 'recipient', and 'participating provider', while also specifying the nature of participating healthcare facilities that manage these donations. Under this bill, it is permitted for individuals to donate their unused prescription drugs to specified healthcare providers to be redistributed to others in need, provided these drugs meet certain health and safety standards.

Sentiment

General sentiment towards SB382 is largely positive, particularly from segments of the healthcare community and consumer advocates who argue that the bill promotes a sustainable approach to manage unused medications. The bill's supporters view it as beneficial not only to those receiving the drugs but also to the environment, as it facilitates the reduction of pharmaceutical waste. However, there are concerns raised regarding the potential risks associated with redistributing pharmaceutical products, particularly around ensuring the drugs’ safety and efficacy.

Contention

Notable points of contention regarding SB382 stem from the concerns about liability and safety. While the bill does provide some level of liability protection for donors, participating providers, and manufacturers, critics argue this may not be sufficient to address potential issues of mishandling or adverse reactions from recipients of donated drugs. Furthermore, the stipulations surrounding the various roles within the donation process, including the necessity for proper insurance and the limitations on herbal or controlled substances, raise questions about the feasibility of such a program as a comprehensive solution for drug waste management.